Alder Drug Fights Cancer Fatigue
Luke Timmerman6/1/09
Alder Biopharmaceuticals, the Bothell, WA-based developer of targeted antibody drugs, said today that its lead drug candidate was found to be safe and reduce severe fatigue of patients in an early-stage study of patients with advanced cancer. The trial enrolled nine patients who got ALD518, an antibody that’s designed to block an inflammatory protein called IL-6. The preliminary results were presented at the American Society of Clinical Oncology meeting in Orlando, FL. The drug is now being tested in a larger study of 124 cancer patients, which is expected to complete enrollment by the end of 2009.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
